Physician profile
Kelly M Chewning
NPI 1760465744
$10,844.16
in general payments reported to CMS, 2019-2025
14 companies · $6,024 in 2025
The $6,024 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $112 · 2023: $720 · 2024: $3,874 · 2025: $6,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,339 · Food and Beverage: $3,898 · Consulting Fee: $250 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,338.58 |
| Food and Beverage | $3,898.05 |
| Consulting Fee | $250.00 |
| Education | $131.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $6,339.81 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Mitris Resilia Mitral Valve |
| Medtronic, INC. | $3,190.45 | 2023-2025 | Corevalve Evolut R, Apollotm |
| Abbott Laboratories | $316.16 | 2025 | Triclip, Navitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.76 | 2023-2024 | Jardiance |
| Pharming Healthcare, INC. | $130.00 | 2024 | Ruconest |
| Boston Scientific Corporation | $125.38 | 2024 | Watchman Flx |
| Teva Pharmaceuticals USA, INC. | $115.84 | 2025 | Austedo Xr |
| Zoll Respicardia, INC. | $114.86 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $90.37 | 2024 | Inpefa |
| Philips North America LLC | $61.25 | 2024-2025 | (Ck4) Mcot, Ecc Solutions |
| Abiomed | $59.32 | 2024 | Impella |
| Alexion Pharmaceuticals, INC. | $44.95 | 2022 | |
| Jenavalve Technology, INC. | $39.87 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Chewning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.